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Over recent years combined modality therapy has become ﬁrmly es-
tablished as a standard in the treatment of patients with locoregionally 
advanced unresectable non-small cell lung cancer (NSCLC). In direct 
comparison, concomitant chemoradiotherapy was shown repeatedly 
to be superior to induction chemotherapy. A case can be made that 
concomitant chemoradiotherapy primarily addresses locoregional dis-
ease while induction chemotherapy might be better suited to eradicate 
distant micrometastatic foci. Therefore, continuing sequential and con-
comitant therapy might be beneﬁcial and the addition of induction or 
adjuvant chemotherapy to the concomitant chemoradiotherapy standard 
have been investigated. 
CALGB 39801 compared concomitant chemoradiotherapy using the 
carboplatin paclitaxel platform versus induction chemotherapy with 
carboplatin and paclitaxel for two cycles followed by identical chemo-
radiotherapy. While a numerical trend favored the induction chemo-
therapy arm, there was no signiﬁcant advantage for overall survival. 
Similarly, the Hoosier Oncology Group evaluated the administration of 
concomitant chemoradiotherapy using the cisplatin etoposide platform 
with or without three additional cycles of consolidation chemotherapy 
with docetaxel. This study was based on promising pilot data generated 
by the Southwest Oncology Group. Again, the study showed no signiﬁ-
cant survival advantage from the addition of concomitant chemoradio-
therapy. Therefore, at the present time, concomitant chemoradiotherapy 
should be regarded as the standard approach for most patients with 
unresectable non-small cell lung cancer. 
Induction chemotherapy may have a role for patients with poor perfor-
mance status who may not be candidates to undergo aggressive chemo-
radiotherapy. Certain targeted agents might be appropriate to investi-
gate in the consolidation setting under carefully deﬁned experimental 
conditions. This need is highlighted by the recent experience in SWOG 
0023 in which the administration of geﬁtinib as maintenance therapy 
was found to decrease survival rates. 
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The lung is an internal organ consisting of a complex branching system 
of airways leading to gas exchange units. Lung cancer consists of 
several cell types instead of a single cell type. Different cell types are 
preferentially located in different parts of the bronchial tree. There is no 
single method that can detect pre-invasive cancer in the entire bronchial 
epithelium and allow simultaneous tissue sampling for pathological 
diagnosis and molecular proﬁling. While computerized tomography, 
magnetic resonance imaging and ultrasound can detect objects in the 
sub-milliliter scale, photonic imaging can detect structural and func-
tional changes in cells and tissues down to the micron and sub-micron 
